The value of serum creatinine as biomarker of disease progression in spinal and bulbar muscular atrophy (SBMA).
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
12 10 2023
12 10 2023
Historique:
received:
21
08
2023
accepted:
08
10
2023
medline:
1
11
2023
pubmed:
13
10
2023
entrez:
12
10
2023
Statut:
epublish
Résumé
Serum creatinine has been indicated as a potential marker of motor function in SBMA and results form previous longitudinal studies pointed to its decline over time. This is a longitudinal retrospective study investigating creatinine changes over a 36-month-period in 73 patients with SBMA. Severity and progression of the disease was assessed according to serum creatine kinase (CK) values, manual muscle testing (MMT), SBMA functional rating scale (SBMAFRS) score, 6-min-walk test (6MWT) value, and spirometry (forced vital capacity, fVC%) obtained at the baseline and at each of the annual follow-up visits. Baseline serum creatinine concentrations positively correlated with 6MWT, the MMT megascore score of both the upper (ULM) and lower (LLM) limbs and SBMAFRS. No correlation was found with CK or fVC% values. Similar correlation results were achieved at all the subsequent time points. Longitudinal assessments conducted by the generalized estimating equations (GEE) method returned significant changes for SBMAFRS (- 1.41 points per year, p < 0.001), ULM and LLM (- 0.69, p = 0.01; and - 1.07, p < 0.001, respectively), 6MWT (- 47 m, p < 0.001) but not for creatinine (- 0.82, p > 0.05). We also observed that creatinine levels at baseline did not correlate with changes in the other measures from baseline at each annual visit. Our data do not support a role for serum creatinine as sensitive biomarker of disease progression, and possibily prognosis, in SBMA.
Identifiants
pubmed: 37828349
doi: 10.1038/s41598-023-44419-6
pii: 10.1038/s41598-023-44419-6
pmc: PMC10570332
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Biomarkers
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
17311Informations de copyright
© 2023. Springer Nature Limited.
Références
Fischbeck, K. H. Kennedy disease. J. Inherit. Metab. Dis. 20(2), 152–158. https://doi.org/10.1023/a:1005344403603 (1997).
doi: 10.1023/a:1005344403603
pubmed: 9211187
La Spada, A. R., Wilson, E. M., Lubahn, D. B., Harding, A. E. & Fischbeck, K. H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature. 352(6330), 77–79. https://doi.org/10.1038/352077a0 (1991).
doi: 10.1038/352077a0
pubmed: 2062380
Chahin, N., Klein, C., Mandrekar, J. & Sorenson, E. Natural history of spinal-bulbar muscular atrophy. Neurology. 70(21), 1967–1971. https://doi.org/10.1212/01.wnl.0000312510.49768.eb (2008).
doi: 10.1212/01.wnl.0000312510.49768.eb
pubmed: 18490617
Sorarù, G. et al. Muscle histopathology in upper motor neuron-dominant amyotrophic lateral sclerosis. Amyotroph. Lateral. Scler. 9(5), 287–293. https://doi.org/10.1080/17482960802206801 (2008).
doi: 10.1080/17482960802206801
pubmed: 18608096
Monks, D. A. et al. Androgen receptor and Kennedy disease/spinal bulbar muscular atrophy. Horm Behav. 53(5), 729–740. https://doi.org/10.1016/j.yhbeh.2007.12.009 (2008) (Epub 2008 Jan 5).
doi: 10.1016/j.yhbeh.2007.12.009
pubmed: 18321505
pmcid: 2883265
Cortes, C. J. et al. Muscle expression of mutant androgen receptor accounts for systemic and motor neuron disease phenotypes in spinal and bulbar muscular atrophy. Neuron. 82(2), 295–307. https://doi.org/10.1016/j.neuron.2014.03.001 (2014).
doi: 10.1016/j.neuron.2014.03.001
pubmed: 24742458
pmcid: 4096235
Cortes, C. J. & La Spada, A. R. Motor neuron degeneration in spinal and Bulbar Muscular Atrophy is a skeletal muscle-driven process: Relevance to therapy development and implications for related motor neuron diseases. Rare Dis. 2(1), e962402. https://doi.org/10.4161/2167549X.2014.962402 (2014).
doi: 10.4161/2167549X.2014.962402
pubmed: 26942099
pmcid: 4755247
Querin, G. et al. Non-neural phenotype of spinal and bulbar muscular atrophy: results from a large cohort of Italian patients. J. Neurol. Neurosurg. Psychiatry. 87(8), 810–816. https://doi.org/10.1136/jnnp-2015-311305 (2016) (Epub 2015 Oct 26).
doi: 10.1136/jnnp-2015-311305
pubmed: 26503015
Manzano, R. et al. Beyond motor neurons: Expanding the clinical spectrum in Kennedy’s disease. J. Neurol. Neurosurg. Psychiatry. 89(8), 808–812. https://doi.org/10.1136/jnnp-2017-316961 (2018) (Epub 2018 Jan 20).
doi: 10.1136/jnnp-2017-316961
pubmed: 29353237
Hashizume, A., Fischbeck, K. H., Pennuto, M., Fratta, P. & Katsuno, M. Disease mechanism, biomarker and therapeutics for spinal and bulbar muscular atrophy (SBMA). J. Neurol. Neurosurg. Psychiatry. 91(10), 1085–1091. https://doi.org/10.1136/jnnp-2020-322949 (2020).
doi: 10.1136/jnnp-2020-322949
pubmed: 32934110
Querin, G., Bede, P., Marchand-Pauvert, V. & Pradat, P. F. Biomarkers of spinal and bulbar muscle atrophy (SBMA): A comprehensive review. Front. Neurol. 9, 844. https://doi.org/10.3389/fneur.2018.00844 (2018).
doi: 10.3389/fneur.2018.00844
pubmed: 30364135
pmcid: 6191472
Takeuchi, Y. et al. Walking capacity evaluated by the 6-minute walk test in spinal and bulbar muscular atrophy. Muscle Nerve. 38(2), 964–971. https://doi.org/10.1002/mus.21077 (2008).
doi: 10.1002/mus.21077
pubmed: 18642379
Dahlqvist, J. R. et al. Disease progression and outcome measures in spinobulbar muscular atrophy. Ann. Neurol. 84(5), 754–765. https://doi.org/10.1002/ana.25345 (2018) (Epub 2018 Oct 25).
doi: 10.1002/ana.25345
pubmed: 30255951
Klickovic, U. et al. Skeletal muscle MRI differentiates SBMA and ALS and correlates with disease severity. Neurology. 93(9), e895–e907. https://doi.org/10.1212/WNL.0000000000008009 (2019) (Epub 2019 Aug 7).
doi: 10.1212/WNL.0000000000008009
pubmed: 31391248
pmcid: 6745729
Pennuto, M., Greensmith, L., Pradat, P. F. & Sorarù, G. 210th ENMC International Workshop: Research and clinical management of patients with spinal and bulbar muscular atrophy, 27–29 March, 2015, Naarden, The Netherlands. Neuromusc. Disord. 25(10), 802–812. https://doi.org/10.1016/j.nmd.2015.06.462 (2015) (Epub 2015 Jun 19).
doi: 10.1016/j.nmd.2015.06.462
pubmed: 26206601
Sabbatini, D. et al. Evaluation of peripherin in biofluids of patients with motor neuron diseases. Ann. Clin. Transl. Neurol. 8(8), 1750–1754. https://doi.org/10.1002/acn3.51419 (2021) (Epub 2021 Jul 15).
doi: 10.1002/acn3.51419
pubmed: 34264016
pmcid: 8351396
Patel, S. S. et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: Results of a cross-sectional study and review of literature. J. Cachexia Sarcopenia Muscle. 4(1), 19–29. https://doi.org/10.1007/s13539-012-0079-1 (2013) (Epub 2012 Jul 10).
doi: 10.1007/s13539-012-0079-1
pubmed: 22777757
Bessman, S. P. & Geiger, P. J. Transport of energy in muscle: The phosphorylcreatine shuttle. Science. 211(4481), 448–452. https://doi.org/10.1126/science.6450446 (1981).
doi: 10.1126/science.6450446
pubmed: 6450446
Baxmann, A. C. et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin. J. Am. Soc. Nephrol. 3(2), 348–354. https://doi.org/10.2215/CJN.02870707 (2008) (Epub 2008 Jan 30).
doi: 10.2215/CJN.02870707
pubmed: 18235143
pmcid: 2390952
Schutte, J. E., Longhurst, J. C., Gaffney, F. A., Bastian, B. C. & Blomqvist, C. G. Total plasma creatinine: An accurate measure of total striated muscle mass. J. Appl. Physiol. Respir. Environ. Exerc. Physiol. 51(3), 762–766. https://doi.org/10.1152/jappl.1981.51.3.762 (1981).
doi: 10.1152/jappl.1981.51.3.762
pubmed: 7327978
Alves, C. R. R. et al. Serum creatinine is a biomarker of progressive denervation in spinal muscular atrophy. Neurology. 94(9), e921–e931. https://doi.org/10.1212/WNL.0000000000008762 (2020) (Epub 2019 Dec 27).
doi: 10.1212/WNL.0000000000008762
pubmed: 31882526
pmcid: 7238944
Viollet, L. et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 40(3), 438–442. https://doi.org/10.1002/mus.21420 (2009).
doi: 10.1002/mus.21420
pubmed: 19623638
pmcid: 2740988
Van Eijk, R. P. A. et al. Monitoring disease progression with plasma creatinine in amyotrophic lateral sclerosis clinical trials. J. Neurol. Neurosurg. Psychiatry. 89(2), 156–161. https://doi.org/10.1136/jnnp-2017-317077 (2018) (Epub 2017 Oct 30).
doi: 10.1136/jnnp-2017-317077
pubmed: 29084868
Holdom, C. J. et al. Venous creatinine as a biomarker for loss of fat-free mass and disease progression in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 28(11), 3615–3625. https://doi.org/10.1111/ene.15003 (2021) (Epub 2021 Aug 9).
doi: 10.1111/ene.15003
pubmed: 34216521
Hashizume, A. et al. A functional scale for spinal and bulbar muscular atrophy: Cross-sectional and longitudinal study. Neuromusc. Disord. 25(7), 554–562. https://doi.org/10.1016/j.nmd.2015.03.008 (2015) (Epub 2015 Mar 20).
doi: 10.1016/j.nmd.2015.03.008
pubmed: 25913211
Querin, G. et al. Validation of the Italian version of the SBMA functional rating scale as outcome measure. Neurol. Sci. 37(11), 1815–1821. https://doi.org/10.1007/s10072-016-2666-y (2016) (Epub 2016 Jul 21).
doi: 10.1007/s10072-016-2666-y
pubmed: 27444956
Harris-Love, M. O. et al. Assessing function and endurance in adults with spinal and bulbar muscular atrophy: Validity of the adult myopathy assessment tool. Rehabil. Res. Pract. 2014, 873872. https://doi.org/10.1155/2014/873872 (2014) (Epub 2014 May 5).
doi: 10.1155/2014/873872
pubmed: 24876969
pmcid: 4026974
Hashizume, A. et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain. 135(Pt 9), 2838–2848. https://doi.org/10.1093/brain/aws170 (2012) (Epub 2012 Jul 6).
doi: 10.1093/brain/aws170
pubmed: 22773541
Lombardi, V. et al. Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology. 92(11), e1205–e1211. https://doi.org/10.1212/WNL.0000000000007097 (2019) (Epub 2019 Feb 20; Erratum in: Neurology. 2020;94(19):852).
doi: 10.1212/WNL.0000000000007097
pubmed: 30787165
pmcid: 6511101
Hijikata, Y. et al. Biomarker-based analysis of preclinical progression in spinal and bulbar muscular atrophy. Neurology. 90(17), e1501–e1509. https://doi.org/10.1212/WNL.0000000000005360 (2018) (Epub 2018 Mar 23).
doi: 10.1212/WNL.0000000000005360
pubmed: 29572281
Wyss, M. & Kaddurah-Daouk, R. Creatine and creatinine metabolism. Physiol. Rev. 80(3), 1107–1213. https://doi.org/10.1152/physrev.2000.80.3.1107 (2000).
doi: 10.1152/physrev.2000.80.3.1107
pubmed: 10893433
Swaminathan, R., Ho, C. S., Chu, L. M. & Donnan, S. Relation between plasma creatinine and body size. Clin Chem. 32(2), 371–373 (1986).
doi: 10.1093/clinchem/32.2.371
pubmed: 3943202
Thongprayoon, C., Cheungpasitporn, W. & Kashani, K. Serum creatinine level, a surrogate of muscle mass, predicts mortality in critically ill patients. J. Thorac. Dis. 8(5), E305–E311. https://doi.org/10.21037/jtd.2016.03.62 (2016).
doi: 10.21037/jtd.2016.03.62
pubmed: 27162688
pmcid: 4842835
Banfi, G., Del Fabbro, M. & Lippi, G. Serum creatinine concentration and creatinine-based estimation of glomerular filtration rate in athletes. Sports Med. 39(4), 331–337. https://doi.org/10.2165/00007256-200939040-00005 (2009).
doi: 10.2165/00007256-200939040-00005
pubmed: 19317520
Hijikata, Y. et al. Impaired muscle uptake of creatine in spinal and bulbar muscular atrophy. Ann. Clin. Transl. Neurol. 3(7), 537–546. https://doi.org/10.1002/acn3.324 (2016).
doi: 10.1002/acn3.324
pubmed: 27386502
pmcid: 4931718
Querin, G. et al. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology. 80(23), 2095–2098. https://doi.org/10.1212/WNL.0b013e318295d766 (2013) (Epub 2013 May 3).
doi: 10.1212/WNL.0b013e318295d766
pubmed: 23645595
Atsuta, N. et al. Natural history of spinal and bulbar muscular atrophy (SBMA): A study of 223 Japanese patients. Brain. 129(Pt 6), 1446–1455. https://doi.org/10.1093/brain/awl096 (2006) (Epub 2006 Apr 18).
doi: 10.1093/brain/awl096
pubmed: 16621916
Ambrosini, A. et al. The Italian neuromuscular registry: A coordinated platform where patient organizations and clinicians collaborate for data collection and multiple usage. Orphanet. J. Rare Dis. 13(1), 176. https://doi.org/10.1186/s13023-018-0918-z (2018).
doi: 10.1186/s13023-018-0918-z
pubmed: 30286784
pmcid: 6172847